Nothing Special   »   [go: up one dir, main page]

CY1112787T1 - Πολλαπλομερη του υποδοχεα κυτοκινης ζcytor17 - Google Patents

Πολλαπλομερη του υποδοχεα κυτοκινης ζcytor17

Info

Publication number
CY1112787T1
CY1112787T1 CY20121100477T CY121100477T CY1112787T1 CY 1112787 T1 CY1112787 T1 CY 1112787T1 CY 20121100477 T CY20121100477 T CY 20121100477T CY 121100477 T CY121100477 T CY 121100477T CY 1112787 T1 CY1112787 T1 CY 1112787T1
Authority
CY
Cyprus
Prior art keywords
receptor17
multiplomerometer
amino acid
acid residues
zcytor17
Prior art date
Application number
CY20121100477T
Other languages
English (en)
Inventor
Cindy A Sprecher
Zeren Gao
Joseph L Kuijper
Maria M Dasovich
Francis J Grant
Scott R Presnell
Theodore E Whitmore
Angela K Hammond
Julia E Novak
Jane A Gross
Stacey R Dillon
Original Assignee
Zymogenetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics, Inc. filed Critical Zymogenetics, Inc.
Publication of CY1112787T1 publication Critical patent/CY1112787T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Καινοφανείς συνδυασμοί πολυπεπτιδίων, πολυνουκλεοτίδια που εγκωδικεύουν τα πολυπεπτίδια, και σχετικές συνθέσεις και μέθοδοι αποκαλύπτονται για τους περιέχοντες-zcytor17 πολλαπλομερικούς ή ετεροδιμερικούς υποδοχείς κυτοκινών που μπορεί να χρησιμοποιηθούν ως καινοφανείς ανταγωνιστές κυτοκινών, και εντός των πλαισίων μεθόδων για την ανίχνευση προσδετών που διεγείρουν την υπερπλασία και/ή ανάπτυξη αιμοποιητικών, λεμφοειδών και μυελοειδών κυττάρων in vitro και in vivo. Η παρούσα εφεύρεση συμπεριλαμβάνει επίσης μεθόδους για την παραγωγή του πολλαπλομερικού ή ετεροδιμερικού υποδοχέα κυτοκίνης, χρήσεις για αυτόν και αντισώματα έναντι αυτού.
CY20121100477T 2002-01-18 2012-05-25 Πολλαπλομερη του υποδοχεα κυτοκινης ζcytor17 CY1112787T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35032502P 2002-01-18 2002-01-18
US38910802P 2002-06-14 2002-06-14
US43536102P 2002-12-19 2002-12-19
EP03761891A EP1576112B1 (en) 2002-01-18 2003-01-21 Cytokine receptor zcytor17 multimers

Publications (1)

Publication Number Publication Date
CY1112787T1 true CY1112787T1 (el) 2016-02-10

Family

ID=30003762

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100477T CY1112787T1 (el) 2002-01-18 2012-05-25 Πολλαπλομερη του υποδοχεα κυτοκινης ζcytor17

Country Status (13)

Country Link
US (24) US7494804B2 (el)
EP (3) EP1576112B1 (el)
JP (2) JP4511349B2 (el)
AT (1) ATE547430T1 (el)
AU (1) AU2003280410B8 (el)
CA (1) CA2473733C (el)
CY (1) CY1112787T1 (el)
DK (1) DK1576112T3 (el)
ES (2) ES2546797T3 (el)
IL (3) IL226637A (el)
PT (1) PT1576112E (el)
SI (1) SI1576112T1 (el)
WO (1) WO2004003140A2 (el)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60043728D1 (de) * 1999-06-02 2010-03-11 Chugai Pharmaceutical Co Ltd Neues hämopoietin rezeptorprotein nr10
EP1221482B1 (en) * 1999-09-27 2005-12-28 Chugai Seiyaku Kabushiki Kaisha Hemopoietin receptor protein, nr12
US20030096339A1 (en) 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
CA2473733C (en) 2002-01-18 2014-09-09 Zymogenetics, Inc. Cytokine receptor zcytor17 multimers
ES2310660T3 (es) 2002-01-18 2009-01-16 Zymogenetics, Inc. Citoquina (ligando zcytor17).
US9738700B2 (en) 2002-01-18 2017-08-22 Zymogenetics Inc. ZCYTOR17 heterodimeric cytokine receptor
JP2007068402A (ja) * 2003-12-26 2007-03-22 Bml Inc 免疫応答調節蛋白質
US20060269991A1 (en) * 2004-11-03 2006-11-30 Boehringer Ingelheim Pharmaceuticals, Inc. T cell protein and nucleotides encoding the same
AU2006207945B2 (en) * 2005-01-28 2012-02-09 Zymogenetics, Inc. Homogeneous preparations of IL-31
AU2012202218B2 (en) * 2005-02-14 2014-05-22 National Jewish Medical And Research Center Methods Of Treating Diseases Which Are Mediated By Cutaneous Lymphocyte Antigen Positive Cells
EP1858924A1 (en) 2005-02-14 2007-11-28 ZymoGenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
WO2006088955A2 (en) * 2005-02-14 2006-08-24 Zymogenetics, Inc. Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
CA2607588A1 (en) * 2005-05-06 2006-11-16 Zymogenetics, Inc. Il-31 monoclonal antibodies and methods of use
US20130216542A1 (en) 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
US7972776B2 (en) 2005-11-15 2011-07-05 Oncohealth Corporation Protein chips for HPV detection
US7638126B2 (en) 2006-01-10 2009-12-29 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using antagonists of IL-31, IL31Ra and/or OSMRb
CN101479381B (zh) * 2006-03-31 2015-04-29 中外制药株式会社 调控抗体血液动力学的方法
CA2654623C (en) 2006-06-08 2016-07-26 Chugai Seiyaku Kabushiki Kaisha An anti-nr10/il-31ra antibody for use in preventing or treating an inflammatory disease
US7851144B2 (en) 2006-08-18 2010-12-14 The University Of Washington Compositions and methods for detecting cancer
EP2054441A1 (en) * 2006-08-25 2009-05-06 Zymogenetics, Inc. Soluble il-27 receptor
DK2594586T3 (en) 2006-09-01 2014-11-17 Zymogenetics Inc Monoclonal il-31 antibodies and methods of use thereof
US8278056B2 (en) 2008-06-13 2012-10-02 Oncohealth Corp. Detection of early stages and late stages HPV infection
US8968995B2 (en) 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
EP2061496A2 (en) * 2007-01-10 2009-05-27 Zymogenetics, Inc. Methods of using il-31 to treat airway hyper-responsiveness and asthma
CN106519025B (zh) 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
KR101922788B1 (ko) * 2007-09-26 2018-11-27 추가이 세이야쿠 가부시키가이샤 항체 정상영역 개변체
AU2008332276B2 (en) 2007-12-05 2014-02-27 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
KR101643005B1 (ko) * 2007-12-05 2016-07-28 추가이 세이야쿠 가부시키가이샤 항ｎｒ１０ 항체 및 그의 이용
NO2796466T3 (el) 2007-12-07 2018-04-21
KR102057826B1 (ko) * 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
WO2010107109A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
JP6030452B2 (ja) 2010-11-30 2016-11-24 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
AU2012207456C1 (en) 2011-01-18 2017-05-04 Bioniz Therapeutics, Inc. Compositions and methods for modulating gamma-c-cytokine activity
PT3004167T (pt) 2013-05-30 2018-11-13 Kiniksa Pharmaceuticals Ltd Proteínas de ligação ao antigénio do recetor da oncostatina m
WO2015164107A1 (en) 2014-04-23 2015-10-29 Emory University Compositions of gm-csf and interleukin fusions for immune modulation and uses related thereto
CA2980992C (en) 2015-04-14 2024-01-23 Akihisa Kaneko Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
KR102514173B1 (ko) 2015-04-14 2023-03-27 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
CN108135504B (zh) 2015-09-23 2021-08-24 皇家飞利浦有限公司 具有可互换模块的模块化监控设备平台
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
EP3630163A4 (en) 2017-05-24 2021-06-09 Pandion Operations, Inc. TARGETED IMMUNTOLERANCE
US10322165B2 (en) * 2017-07-26 2019-06-18 Academia Sinica TIFA antagonists and their use for treating diseases
KR102414120B1 (ko) 2017-08-03 2022-06-28 암젠 인크 인터류킨-21 뮤테인 및 치료 방법
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
BR112020014121A2 (pt) 2018-01-12 2020-12-01 Amgen Inc. anticorpos anti-pd-1 e métodos de tratamento
WO2020227019A1 (en) 2019-05-03 2020-11-12 Bioniz, Llc Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
MX2021014178A (es) 2019-05-20 2022-01-04 Pandion Operations Inc Inmunotolerancia dirigida a la molecula de adhesion celular de adresina vascular de mucosas (madcam).
KR102416078B1 (ko) 2019-11-20 2022-07-01 추가이 세이야쿠 가부시키가이샤 항체 함유 제제
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
EP4172175A4 (en) * 2020-06-24 2024-07-24 Bioniz Therapeutics Inc ANTAGONISTIC PEPTIDE DIRECTED AGAINST IL-2, IL-9 AND IL-15 FOR THE TREATMENT OF CYTOKINE RELEASE SYNDROME AND CYTOKINE STORM-RELATED DISEASES
EP4209227A4 (en) 2020-09-01 2024-05-29 Chugai Seiyaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF PRURITUS IN DIALYSIS CONTAINING AN IL-31 ANTAGONIST AS ACTIVE INGREDIENT

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK368882A (da) 1981-08-25 1983-02-26 Alan John Kingsman Expessions vektorer
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4661454A (en) 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
CA1280080C (en) 1984-12-06 1991-02-12 Jacques Oberto Promoters for the expression of foreign genes in yeast, plasmids comprising them, and uses thereof for the production of polypeptides
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5063154A (en) 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
DE68926888T2 (de) 1988-01-22 1997-01-09 Zymogenetics Inc Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
CA2097291A1 (en) 1990-12-13 1992-06-14 David P. Gearing Leukemia inhibitory factor receptors
JP3202999B2 (ja) 1991-01-31 2001-08-27 協和醗酵工業株式会社 肝移行性リポソーム製剤
US5298418A (en) 1991-09-16 1994-03-29 Boyce Thompson Institute For Plant Research, Inc. Cell line isolated from larval midgut tissue of Trichoplusia ni
EP0749319A1 (en) 1992-09-14 1996-12-27 Pfizer Inc. Immortalized cells and uses therefor
AU7477394A (en) 1993-07-30 1995-03-27 University Of Medicine And Dentistry Of New Jersey Efficient gene transfer into primary lymphocytes
CA2169190A1 (en) 1994-02-14 1995-08-17 Richard D. Holly Method for preparing orphan receptor ligands
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5783672A (en) * 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
JP4079461B2 (ja) * 1994-12-29 2008-04-23 中外製薬株式会社 Ｉｌ−６アンタゴニストを含んでなる抗腫瘍剤の作用増強剤
US6074849A (en) * 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
WO1997017451A2 (en) 1995-11-09 1997-05-15 Zymogenetics, Inc. Production of gad65 in methylotrophic yeast
US5792850A (en) * 1996-05-23 1998-08-11 Zymogenetics, Inc. Hematopoietic cytokine receptor
WO1998002536A2 (en) 1996-07-17 1998-01-22 Zymogenetics, Inc. Preparation of pichia methanolica auxotrophic mutants
JP2002515746A (ja) 1996-07-17 2002-05-28 ザイモジェネティクス，インコーポレイティド ピヒア・メタノリカの形質転換
PT1500329E (pt) 1996-12-03 2012-06-18 Amgen Fremont Inc Anticorpos humanos que se ligam especificamente ao tnf alfa humano
GB9819420D0 (en) 1998-09-07 1998-10-28 Glaxo Group Ltd Novel receptor
MXPA01012331A (es) 1999-06-01 2002-07-30 Schering Corp Proteinas receptoras de mamiferos, reactivos y metodos relacionados.
DE60043728D1 (de) * 1999-06-02 2010-03-11 Chugai Pharmaceutical Co Ltd Neues hämopoietin rezeptorprotein nr10
BR0015055A (pt) * 1999-10-20 2002-07-16 Genentech Inc Método de aumento estimulação ou potencialização da diferenciação de células t, método de tratamento de uma doença mediada por th1 em um mamìfero, método de prevenir, inibir ou atenuar a diferenciação de céluas t, método de tratamento de uma doença mediada por th2, em um mamìfero, método de determinação da presença de polipeptìdeo tccr em uma célula, método de diagnóstico de doenças mediadas por th1 ou mediadas por th2 em um mamìfero, método de identificação de compostos capazes de inibir a expressão de polipeptìdeos tccr e método para identificação de compostos capazes de inibir a atividade biológica de polipeptìdeo tccr, uso de antagonistas e agonistas de polipeptìdeos tccr
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001278852A1 (en) 2000-06-23 2002-01-08 Genentech Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
PT1325115T (pt) 2000-06-26 2016-09-28 Zymogenetics Inc Recetor de citocina zcytor17
US20030096339A1 (en) * 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
MXPA03002971A (es) * 2000-10-06 2004-05-05 Immunex Corp Receptores de hematopoyetina hpr1 y hpr2.
WO2002077230A1 (fr) 2001-03-26 2002-10-03 Chugai Seiyaku Kabushiki Kaisha Variants d'epissage nr10
ES2310660T3 (es) * 2002-01-18 2009-01-16 Zymogenetics, Inc. Citoquina (ligando zcytor17).
CA2473733C (en) * 2002-01-18 2014-09-09 Zymogenetics, Inc. Cytokine receptor zcytor17 multimers
JP2005518212A (ja) * 2002-02-25 2005-06-23 ジェネンテック・インコーポレーテッド 新規な１型サイトカインレセプターｇｌｍ−ｒ
US7552497B2 (en) * 2002-03-26 2009-06-30 Colgate-Palmolive Company Powered toothbrush with rotating sections
EP1858924A1 (en) * 2005-02-14 2007-11-28 ZymoGenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist

Also Published As

Publication number Publication date
CA2473733C (en) 2014-09-09
US20170320931A1 (en) 2017-11-09
ES2546797T3 (es) 2015-09-28
EP1576112A4 (en) 2007-09-05
IL226637A (en) 2017-11-30
US8647866B2 (en) 2014-02-11
US20140141485A1 (en) 2014-05-22
US20180346584A1 (en) 2018-12-06
EP2338910A1 (en) 2011-06-29
JP4511349B2 (ja) 2010-07-28
AU2003280410A1 (en) 2004-01-19
US20100266597A1 (en) 2010-10-21
WO2004003140A3 (en) 2005-09-01
US20170204190A1 (en) 2017-07-20
US20070048831A1 (en) 2007-03-01
EP1576112B1 (en) 2012-02-29
IL163067A (en) 2013-07-31
US20110318354A1 (en) 2011-12-29
US20070140963A1 (en) 2007-06-21
JP2010043120A (ja) 2010-02-25
US20130143265A1 (en) 2013-06-06
PT1576112E (pt) 2012-05-25
US20100055101A1 (en) 2010-03-04
US20120264168A1 (en) 2012-10-18
EP1576112A2 (en) 2005-09-21
US20170369580A1 (en) 2017-12-28
CA2473733A1 (en) 2004-01-08
EP2338910B1 (en) 2015-07-08
US20070048833A1 (en) 2007-03-01
US20070048832A1 (en) 2007-03-01
SI1576112T1 (sl) 2012-10-30
US20070048835A1 (en) 2007-03-01
US7494804B2 (en) 2009-02-24
EP2840089A1 (en) 2015-02-25
US20070140964A1 (en) 2007-06-21
US20070049530A1 (en) 2007-03-01
AU2003280410B8 (en) 2009-04-23
US9212213B2 (en) 2015-12-15
JP2006500919A (ja) 2006-01-12
US20070048834A1 (en) 2007-03-01
US20070048222A1 (en) 2007-03-01
WO2004003140A2 (en) 2004-01-08
ES2382800T3 (es) 2012-06-13
US20100266499A1 (en) 2010-10-21
US20070048223A1 (en) 2007-03-01
AU2003280410B2 (en) 2009-04-02
DK1576112T3 (da) 2012-06-25
US10227415B2 (en) 2019-03-12
ATE547430T1 (de) 2012-03-15
IL226637A0 (en) 2013-06-27
US20090274694A1 (en) 2009-11-05
US20160002340A1 (en) 2016-01-07
US20030215838A1 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
CY1112787T1 (el) Πολλαπλομερη του υποδοχεα κυτοκινης ζcytor17
CY1112833T1 (el) Καινοφανης προσδετης της κυτοκινης ζcυτοr17
NO2020016I1 (no) efmoroktokog alfa - forlenget SPC
FI2784084T4 (fi) Antagonistivasta-aineet IL-17A/F heterologisille polypeptideille
CY1109725T1 (el) Ειδικες δεσμευομενες πρωτεϊνες και χρησεις αυτων
DK1642973T3 (da) Terapeutisk anvendelser af BR43X2-oplöselige receptorer
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
UY28641A1 (es) Anticuerpos
HK1077592A1 (zh) 改進型fc融合蛋白質
ATE272114T1 (de) Rezeptoren für il-18
ATE396264T1 (de) Zytokinrezeptoruntereinheit-proteine aus säugetieren, damit zusammenhängende reagenzien und methoden
ATE417275T1 (de) Puffern zur stabilizierung von hcv antigenen
DK1430133T3 (da) En oplöselig Toll-lignende receptor
NZ606260A (en) Novel polypeptides involved in immune response